CAS Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China.
University of Chinese Academy of Sciences, Beijing, 100080, China.
Mol Imaging Biol. 2020 Dec;22(6):1455-1468. doi: 10.1007/s11307-019-01431-5.
Morphological imaging techniques are typically used in the anti-cancer drug efficacy evaluation process. However, these techniques can evaluate the therapeutic efficacy only when the tumor shows anatomic changes-usually at later stages, when the therapeutic effects are poor. In contrast, molecular imaging allows noninvasive monitoring of tumor growth, assessment of drug metabolism, and evaluation of therapeutic efficacy at the molecular and cellular levels. Multimodality molecular imaging, which combines the advantages of various imaging modalities, provides even more comprehensive therapeutic efficacy assessment in preclinical and clinical studies. This review provides an overview of molecular imaging evaluation of therapeutic efficacy of the anti-tumor drugs in hepatocellular carcinoma (HCC) both in preclinical and clinical research, which holds great promise in guiding HCC treatment into the era of precision medicine.
形态学成像技术通常用于抗癌药物疗效评估过程中。然而，这些技术只能在肿瘤出现解剖学变化时（通常在晚期，治疗效果较差时）评估治疗效果。相比之下，分子成像可以在不侵犯的情况下监测肿瘤生长，评估药物代谢，并在分子和细胞水平上评估治疗效果。多模态分子成像结合了各种成像方式的优势，为临床前和临床研究中提供了更全面的治疗效果评估。本文综述了分子成像在肝癌（HCC）的临床前和临床研究中评估抗肿瘤药物疗效的应用，为指导 HCC 治疗进入精准医学时代提供了新的契机。
